Step 1

Draft

Step 2

Unite with Fellow Investors

Step 3

Choose the Best Attorney

Step 4

Provide Documents

Step 5

Follow Case Progress

Step 6

Get Payout

MYL.US

id: 1801

Mylan N.V. ($MYL)$60M Investor Settlement

Eligible claimants can submit their claims for compensation.

$60,000,000

Cash Settlement

W.D. Pennsylvania

Court

2:20-cv-00955

Case number

02/16/2016

Class period Start

05/07/2019

Class period End

07/10/2026

Claim deadline

Mylan N.V. has reached a $60M settlement with $MYL investors to resolve claims that it engaged in a years-long scheme to fix prices for generic drugs and misled the public about its involvement in anticompetitive conduct.

Outline:

Investors claim Mylan colluded with competitors between 2013 and 2018 to inflate generic drug prices. They say the company publicly claimed compliance with antitrust laws while concealing the alleged scheme.
Reports and investigations later linked Mylan to the conduct, drawing subpoenas and increased scrutiny. As $MYL shares declined, investors sued over what they describe as misleading disclosures and omissions.

Timeline:

April 2016 – Mylan disclosed it had received a subpoena related to drug pricing practices
2017–2019 – Media reports and government investigations linked Mylan to an industry-wide price-fixing scheme
March 2018 – $MYL shares declined as further allegations surfaced
November 13, 2020 – Investors filed suit against Mylan N.V. for misleading disclosures and price-fixing involvement
December 2025 – Mylan agrees to a tentative settlement to resolve all claims

Background:

Investors allege Mylan colluded with other drugmakers between 2013 and 2018 to fix prices and divide market share for generic drugs, including essential medications. They say Mylan publicly denied wrongdoing and claimed compliance with antitrust laws despite the alleged conduct.

Regulatory scrutiny intensified in April 2016 when Mylan disclosed it had received a subpoena related to its drug pricing practices. Between 2017 and 2019, media investigations and government probes further tied Mylan to the broader alleged scheme.

As additional allegations surfaced in March 2018, investors point to a decline in $MYL shares. They claim the market reaction reflected growing concerns about Mylan’s legal exposure and the truthfulness of its public statements.

On November 13, 2020, investors filed a lawsuit alleging Mylan misled shareholders about its involvement and related risks. In 2025, Mylan agreed to a tentative settlement to resolve the claims.

What Can Investors Expect Now?

Mylan N.V. has reached a tentative settlement with $MYL investors to resolve claims that it engaged in a years-long scheme to fix prices for generic drugs and misled the public about its involvement in anticompetitive conduct.

If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section below.

Case Type

US Securities Class Action

Case Status

Accepting Claims

Alleged Offence

Misleading Statements,

Failure to Disclose

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Payout per Share

0.11

Filing date

06/26/2020

Plaintiffs

Public Employees’ Retirement System of Mississippi

Attorneys

Bernstein Litowitz Berger & Grossmann LLP

Defendants

Heather Bresch; Rajiv Malik

Judge

Hon. J. Nicholas Ranjan

Administrator

JND Legal Administration

Settlement agreement date

2026-02-18

Court hearing date

06/15/2026

Exclusion deadline

05/15/2026

Objection deadline

05/15/2026

Attorney fee

$15,500,000

Trades matching type

FIFO

Frequently Asked Questions

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.